跳到正文
原文
BioPharma Dive· Kristin Jensen·· 2026-10-14精选AI 评分64

Verastem的KRAS G12D抑制剂在早期研究中对三种肿瘤显示出疗效

Verastem cancer drug shows early promise in small study

AI 导读

Verastem Oncology周三发布了VS-7375的早期数据,该药物靶向KRAS G12D突变。这项小型研究涵盖了转移性胰腺导管腺癌、转移性结直肠癌和晚期非小细胞肺癌患者。结果显示,胰腺癌患者的客观缓解率为36%至50%,结直肠癌患者为33%,非小细胞肺癌患者为43%。基于这些数据,公司计划在6月底前启动三项后期试验。

推荐理由

报道了Verastem在KRAS G12D抑制剂临床前研究中取得的进展,为行业读者提供了评估竞争格局的参考。

正文 · 原文

An article from site logo

Dive Brief

Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and crowded areas of oncology research.

Published Oct. 14, 2026

Pancreatic cancer cells are stained pink in this micrograph image.

A stained image of pancreatic ductal adenocarcinoma. Getty Images

Dive Brief:

  • Verastem Oncology shares rose 18% Wednesday after the company released highly anticipated early data suggesting its experimental cancer drug could help certain patients with three different types of tumors.
  • The drug, VS-7375, targets the most prevalent of the “KRAS” mutations that drive cancer, one known as G12D. The medicine is designed to bind to both the “on” and “off” states of the mutation, which may allow it to hold back tumor growth more completely than rival treatments that only target one or the other, Verastem said.
  • The small study included patients with metastatic pancreatic ductal adenocarcinoma, metastatic colorectal cancer and advanced non-small cell lung cancer. Based on the results, the company plans to kick off a trio of late-stage trials before the end of June.

Dive Insight:

Verastem’s data give the company an early boost as it vies for attention in one of the hottest areas of cancer research. Revolution Medicines led the way in August, winning Food and Drug Administration approval for Rasonque, which had shown groundbreaking results in pancreatic cancer and is widely expected to generate billions of dollars in sales.

Research released earlier this year showed that Rasonque could almost double survival for pancreatic patients with G12 mutations. But the door may have cracked open for rivals a bit this month, when the FDA released documents suggesting the drug’s effects were varied among the different types of G12 mutations and more modest for G12D, Verastem’s target.

In Verastem’s Phase 1/2 study, researchers looked at how well VS-7375 could reduce signs of cancer in patients, a measure called an “objective response rate.” They found response rates ranging from 36% to 50% in the pancreatic patients, depending on how many lines of treatment they had already undergone. The figure was 33% for the colorectal cancer patients and 43% for those with non-small cell lung cancer.

Those results came close to or exceeded the expectations of Wall Street analysts for each of the indications. The data show “a competitive profile,” RBC Capital Markets analyst Leonid Timashev wrote in a note to clients.

Verastem also chose Wednesday to announce a $250 million stock offering and a transition plan for a new CEO. In all, Verastem is having a “transformative day,” Timashev wrote.

Still, Verastem’s research is in early stages, and its drug needs to succeed in larger pivotal trials. The company said it has already reached alignment with the FDA on a Phase 3 trial in pancreatic cancer that will study VS-7375 as a first-line treatment and begin by the end of the year. It expects to enroll the first patients in colorectal and lung cancer Phase 3 trials in the first half of next year.

Verastem will have plenty of competition. Revolution is also developing a drug, zoldonrasib, specifically designed to target G12D and is working on medicines tailored to other mutations. And KRAS has drawn interest from a range of developers: from major players like Eli Lilly and Roche to smaller companies like Tango Therapeutics, Erasca and BridgeBio Oncology Therapeutics.

Like many pharmaceutical companies in recent years, Verastem looked to China to help build its pipeline by collaborating with GenFleet Therapeutics. GenFleet is developing the drug in China and began its registrational trial late last year.

来源:BioPharma Dive · biopharmadive.com